{"id":"adriamycin-cyclophosphamide-docetaxel","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"50-70","effect":"Nausea/vomiting"},{"rate":"80-90","effect":"Alopecia"},{"rate":"20-40","effect":"Mucositis"},{"rate":"20-35","effect":"Peripheral neuropathy (docetaxel phase)"},{"rate":"5-10","effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":"60-80","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL359744","moleculeType":"Small molecule","molecularWeight":"579.99"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adriamycin (doxorubicin) and cyclophosphamide work synergistically as DNA-damaging agents in the initial phase, followed by docetaxel, a microtubule-stabilizing taxane that prevents cell division. This sequential approach (AC→T) is designed to maximize cytotoxic effect while managing cumulative toxicity, commonly used in breast cancer treatment to target both rapidly dividing tumor cells and micrometastatic disease.","oneSentence":"This sequential chemotherapy regimen uses anthracycline and alkylating agents followed by a taxane to damage cancer cell DNA and disrupt microtubule formation, inducing apoptosis in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:00.588Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (neoadjuvant or adjuvant treatment)"},{"name":"HER2-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT04001829","phase":"PHASE2","title":"Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-08-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":249},{"nctId":"NCT04293393","phase":"PHASE2","title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2020-10-02","conditions":"Early Breast Cancer","enrollment":200},{"nctId":"NCT01928589","phase":"NA","title":"Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Richard Zellars","startDate":"2014-01-16","conditions":"Breast Cancer, Adenocarcinoma of the Breast","enrollment":81},{"nctId":"NCT07441460","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-03-07","conditions":"Resectable HER2-positive Breast Cancer","enrollment":1800},{"nctId":"NCT04024462","phase":"PHASE3","title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT07102940","phase":"PHASE2","title":"Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"George Washington University","startDate":"2026-05-01","conditions":"Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer","enrollment":50},{"nctId":"NCT04570423","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","status":"RECRUITING","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2021-05-20","conditions":"Solid Tumors, Lymphoma","enrollment":40},{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT04290793","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2020-03-01","conditions":"Breast Cancer","enrollment":113},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT05256745","phase":"PHASE1, PHASE2","title":"RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2023-06-06","conditions":"Cancer Related Cognitive Decline, Non-metastatic Breast Cancer","enrollment":48},{"nctId":"NCT05114720","phase":"PHASE3","title":"Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-11-11","conditions":"Breast Cancer","enrollment":559},{"nctId":"NCT06107673","phase":"PHASE2","title":"Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-09-30","conditions":"Breast Cancer","enrollment":144},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT07150767","phase":"PHASE1","title":"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2025-03-26","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":""},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT01710176","phase":"PHASE3","title":"Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2011-06-01","conditions":"Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults","enrollment":550},{"nctId":"NCT05929768","phase":"PHASE3","title":"Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-09-15","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8","enrollment":2400},{"nctId":"NCT05645380","phase":"PHASE2","title":"Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-12-05","conditions":"Triple Negative Breast Cancer, Breast Cancer","enrollment":139},{"nctId":"NCT00872625","phase":"PHASE1","title":"Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-04","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT00295893","phase":"PHASE2","title":"Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2005-09-27","conditions":"Breast Cancer","enrollment":121},{"nctId":"NCT03283384","phase":"PHASE2","title":"Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2019-06-15","conditions":"Breast Neoplasms","enrollment":100},{"nctId":"NCT05900206","phase":"PHASE2","title":"Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-10-26","conditions":"Breast Cancer","enrollment":370},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT06186700","phase":"PHASE2","title":"Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2023-12-25","conditions":"Breast Cancer Female, Breast Cancer Patients, Neoadjuvant Therapy","enrollment":100},{"nctId":"NCT01275677","phase":"PHASE3","title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-08","conditions":"HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma","enrollment":3270},{"nctId":"NCT02455141","phase":"PHASE3","title":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-03","conditions":"Breast Neoplasm","enrollment":786},{"nctId":"NCT01564056","phase":"PHASE3","title":"Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-04-12","conditions":"Breast Cancer","enrollment":1989},{"nctId":"NCT01354522","phase":"PHASE3","title":"TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2011-05","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT05346224","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-04-25","conditions":"Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer","enrollment":900},{"nctId":"NCT01779206","phase":"PHASE2, PHASE3","title":"ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2012-05","conditions":"Breast Cancer","enrollment":4936},{"nctId":"NCT06768931","phase":"PHASE2","title":"Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-30","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer","enrollment":192},{"nctId":"NCT05296746","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer","status":"RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-05-03","conditions":"Breast Cancer Stage II","enrollment":1100},{"nctId":"NCT06795503","phase":"PHASE3","title":"Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-02","conditions":"Triple-negative Breast Cancer","enrollment":1462},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT00798070","phase":"PHASE3","title":"Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2007-02","conditions":"Breast Cancer","enrollment":2017},{"nctId":"NCT06713057","phase":"PHASE2","title":"Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-12-01","conditions":"Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer","enrollment":20},{"nctId":"NCT05165225","phase":"PHASE2","title":"Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-07-13","conditions":"Breast Cancer, HER2-low-expressing Breast Cancer, Hormone Receptor-positive Breast Cancer","enrollment":48},{"nctId":"NCT02229084","phase":"PHASE1, PHASE2","title":"Vaccination of High Risk Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2015-01-14","conditions":"Breast Cancer, Breast Neoplasms","enrollment":58},{"nctId":"NCT03013504","phase":"PHASE3","title":"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients","status":"COMPLETED","sponsor":"Prestige Biopharma Limited","startDate":"2018-02-19","conditions":"HER2 Positive Breast Cancer","enrollment":503},{"nctId":"NCT06669013","phase":"PHASE3","title":"Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2021-05-20","conditions":"Bone Sarcoma, Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma","enrollment":40},{"nctId":"NCT04664972","phase":"PHASE2","title":"Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2018-11-23","conditions":"Triple Negative Breast Cancer","enrollment":212},{"nctId":"NCT03900637","phase":"PHASE2","title":"PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2019-11-08","conditions":"Breast Cancer","enrollment":122},{"nctId":"NCT03425656","phase":"PHASE3","title":"Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2016-07-09","conditions":"Malignant Neoplasm of Breast","enrollment":108},{"nctId":"NCT03493854","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-06-14","conditions":"Early Breast Cancer","enrollment":500},{"nctId":"NCT06470633","phase":"PHASE2","title":"To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-01","conditions":"Breast Cancer, HR+/HER2- Breast Cancer","enrollment":29},{"nctId":"NCT02049905","phase":"PHASE3","title":"Phase 3 Study to Treat Patients With Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"ImmunityBio, Inc.","startDate":"2014-01","conditions":"Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma","enrollment":433},{"nctId":"NCT02441933","phase":"PHASE3","title":"Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2015-09-01","conditions":"Breast Cancer","enrollment":878},{"nctId":"NCT04540692","phase":"PHASE3","title":"Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2021-01-12","conditions":"Breast Cancer","enrollment":444},{"nctId":"NCT05207514","phase":"PHASE3","title":"Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer","status":"TERMINATED","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2022-03-31","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT00003782","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"1999-03","conditions":"Breast Cancer","enrollment":5351},{"nctId":"NCT05474690","phase":"PHASE3","title":"A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer","status":"WITHDRAWN","sponsor":"Henan Cancer Hospital","startDate":"2022-05-11","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT00712881","phase":"PHASE2","title":"Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Cephalon, Inc.","startDate":"2008-10-13","conditions":"Breast Cancer","enrollment":126},{"nctId":"NCT00630032","phase":"PHASE3","title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2007-09","conditions":"Breast Cancer","enrollment":762},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT02641847","phase":"PHASE2, PHASE3","title":"TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2016-01","conditions":"Triple Negative Breast Cancer, Breast Cancer","enrollment":503},{"nctId":"NCT03609047","phase":"PHASE2","title":"Adjuvant Palbociclib in Elderly Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-06-14","conditions":"Breast Cancer Stage II, Breast Cancer Stage III","enrollment":366},{"nctId":"NCT03742986","phase":"PHASE2","title":"Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-05-02","conditions":"Breast Cancer","enrollment":8},{"nctId":"NCT05978648","phase":"PHASE2","title":"Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy","status":"RECRUITING","sponsor":"wang shusen","startDate":"2023-09-20","conditions":"Breast Neoplasms","enrollment":116},{"nctId":"NCT00525759","phase":"PHASE2","title":"Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-07","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT05673629","phase":"PHASE3","title":"Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer","status":"UNKNOWN","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2023-05-30","conditions":"Breast Cancer","enrollment":552},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT00665457","phase":"PHASE2","title":"Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2004-04-15","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT03329378","phase":"PHASE2","title":"Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-01-24","conditions":"Locally Advanced Breast Cancer","enrollment":7},{"nctId":"NCT05883852","phase":"PHASE3","title":"EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-07","conditions":"HER2 Positive Early Breast Cancer","enrollment":1406},{"nctId":"NCT05914753","phase":"NA","title":"Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2023-07-01","conditions":"Breast Cancer, Chemotherapy Effect","enrollment":200},{"nctId":"NCT05901428","phase":"PHASE3","title":"TCb vs EC-T in High Risk ER+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer","enrollment":1736},{"nctId":"NCT00003519","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1998-08-20","conditions":"Breast Cancer","enrollment":2778},{"nctId":"NCT00004125","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-11-16","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00121992","phase":"PHASE3","title":"Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"1999-07","conditions":"Breast Neoplasms","enrollment":1060},{"nctId":"NCT00432172","phase":"PHASE2","title":"Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2007-04-24","conditions":"Breast Cancer","enrollment":189},{"nctId":"NCT00841828","phase":"PHASE2","title":"Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2009-02","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT00129935","phase":"PHASE3","title":"EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2004-02","conditions":"Breast Cancer","enrollment":1384},{"nctId":"NCT02099175","phase":"PHASE2","title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-11","conditions":"Sinonasal Tumors","enrollment":41},{"nctId":"NCT02099188","phase":"PHASE2","title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-11","conditions":"Unresectable Sinonasal Tumors","enrollment":27},{"nctId":"NCT00493870","phase":"PHASE3","title":"TAC Versus TC for Adjuvant Breast Cancer","status":"COMPLETED","sponsor":"US Oncology Research","startDate":"2007-05-29","conditions":"Breast Cancer","enrollment":1961},{"nctId":"NCT05622058","phase":"PHASE1","title":"A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer","status":"TERMINATED","sponsor":"Aileron Therapeutics, Inc.","startDate":"2023-01-09","conditions":"Prevention of Chemotherapy-induced Myelosuppression","enrollment":6},{"nctId":"NCT00773695","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-07","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT05656079","phase":"NA","title":"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT01779050","phase":"PHASE2","title":"Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-12-19","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT02549677","phase":"PHASE4","title":"Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2015-10","conditions":"Breast Neoplasms","enrollment":294},{"nctId":"NCT02419742","phase":"PHASE4","title":"Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-18","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT01646034","phase":"PHASE3","title":"High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2014-09","conditions":"Breast Cancer","enrollment":74},{"nctId":"NCT05483439","phase":"PHASE2","title":"A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2021-10-20","conditions":"Stage II-III Breast Cancer","enrollment":100},{"nctId":"NCT05420454","phase":"PHASE4","title":"A Study for the Neoadjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":1576},{"nctId":"NCT05420467","phase":"PHASE4","title":"A Study for the Adjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":2413},{"nctId":"NCT04293796","phase":"NA","title":"Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2019-10-08","conditions":"Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB","enrollment":60},{"nctId":"NCT01966471","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-31","conditions":"Breast Cancer","enrollment":1846},{"nctId":"NCT05400993","phase":"PHASE2","title":"Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2022-05-23","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT00887536","phase":"PHASE3","title":"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2009-05","conditions":"Breast Cancer","enrollment":1613},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT01547741","phase":"PHASE3","title":"Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2012-04","conditions":"Breast Cancer","enrollment":1871},{"nctId":"NCT05302336","phase":"PHASE4","title":"AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-01","conditions":"Breast Cancer, Chemotherapeutic Toxicity","enrollment":402},{"nctId":"NCT04836156","phase":"PHASE1, PHASE2","title":"Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2021-04-02","conditions":"HER2-negative Early Breast Cancer","enrollment":46},{"nctId":"NCT01929811","phase":"PHASE2","title":"NeoMET Study in Neoadjuvant Treatment of Breast Cancer","status":"TERMINATED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2013-10","conditions":"pCR Rate, BCT Rate, Safety","enrollment":92},{"nctId":"NCT05287308","phase":"NA","title":"Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study","status":"NOT_YET_RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-03","conditions":"Breast Cancer","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Chemotherapy"],"phase":"phase_3","status":"active","brandName":"Adriamycin+Cyclophosphamide>Docetaxel","genericName":"Adriamycin+Cyclophosphamide>Docetaxel","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This sequential chemotherapy regimen uses anthracycline and alkylating agents followed by a taxane to damage cancer cell DNA and disrupt microtubule formation, inducing apoptosis in rapidly dividing cells. Used for Breast cancer (neoadjuvant or adjuvant treatment), HER2-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}